Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BLCO 
Bausch + Lomb Corp (BLCO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: BLCO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $15.14
1 Year Target Price $15.14
| 3 | Strong Buy |
| 3 | Buy |
| 8 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -23.43% | Avg. Invested days 40 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.27B USD | Price to earnings Ratio - | 1Y Target Price 15.14 |
Price to earnings Ratio - | 1Y Target Price 15.14 | ||
Volume (30-day avg) 15 | Beta 0.63 | 52 Weeks Range 10.45 - 21.69 | Updated Date 09/17/2025 |
52 Weeks Range 10.45 - 21.69 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.78 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -5.58% | Operating Margin (TTM) 0.86% |
Management Effectiveness
Return on Assets (TTM) 0.47% | Return on Equity (TTM) -4.02% |
Valuation
Trailing PE - | Forward PE 13.95 | Enterprise Value 9934122904 | Price to Sales(TTM) 1.08 |
Enterprise Value 9934122904 | Price to Sales(TTM) 1.08 | ||
Enterprise Value to Revenue 2.06 | Enterprise Value to EBITDA 22.16 | Shares Outstanding 353865984 | Shares Floating 42131261 |
Shares Outstanding 353865984 | Shares Floating 42131261 | ||
Percent Insiders 88.06 | Percent Institutions 11.29 |
Upturn AI SWOT
Bausch + Lomb Corp
Company Overview
History and Background
Bausch + Lomb was founded in 1853 in Rochester, New York, by John Jacob Bausch and Henry Lomb. Initially a small optical goods shop, it evolved into a global eye health company. Key milestones include the development of Ray-Ban sunglasses for the U.S. military in the 1930s and the introduction of soft contact lenses in the 1970s. Bausch + Lomb went through various ownership changes and IPOs before becoming a standalone publicly traded company again in 2022.
Core Business Areas
- Vision Care: This segment focuses on contact lenses and lens care products, including daily disposable, reusable, and specialty lenses, as well as solutions and rewetting drops.
- Ophthalmic Pharmaceuticals: This segment develops, manufactures, and markets pharmaceutical products for various eye conditions, such as glaucoma, dry eye, and eye infections.
- Surgical: This segment offers surgical devices, instruments, and technologies for cataract and refractive surgery.
Leadership and Structure
Brent Saunders is the Chairman and Chief Executive Officer. The company has a structured organizational model that includes a board of directors and senior management team overseeing each of the core business segments.
Top Products and Market Share
Key Offerings
- ULTRA Contact Lenses: Monthly replacement contact lenses designed for comfortable wear, especially for digital device users. Competitors include Acuvue (JNJ), Air Optix (ALC), and Biofinity (COPR).
- Biotrue ONEday Contact Lenses: Daily disposable contact lenses designed to mimic the natural moisture of the eye. Competitors include Acuvue (JNJ) and Dailies (ALC).
- Lotemax Ophthalmic: A topical corticosteroid used to treat inflammation and pain after eye surgery. Competitors include Pred Forte (AGN) and Durezol (ALC).
- Stellaris PC Vision Enhancement System: A surgical platform for cataract and vitreoretinal surgery. Competitors include Alcon's Centurion and Johnson & Johnson Vision's VERITAS Vision System.
Market Dynamics
Industry Overview
The eye health industry is experiencing growth driven by an aging population, increased prevalence of eye diseases, technological advancements, and growing demand for vision correction and surgical procedures. The contact lens market is competitive with several key players with a few new players emerging with novel technologies. The pharmaceutical market is constantly evolving with new drug delivery and new treatment protocols. The surgical market is also always improving with higher tech machines.
Positioning
Bausch + Lomb is positioned as a leading global eye health company with a broad portfolio of products and services across vision care, ophthalmic pharmaceuticals, and surgical. Its competitive advantages include a strong brand reputation, established distribution network, and innovative product pipeline.
Total Addressable Market (TAM)
The global eye care market is expected to reach hundreds of billions USD. Bausch + Lomb addresses various segments of this market and has significant potential for growth.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Diversified product portfolio
- Global distribution network
- Experienced management team
- Innovative product pipeline
Weaknesses
- High debt levels
- Exposure to generic competition
- Dependence on key products
- Integration challenges from acquisitions
- Currency fluctuations
Opportunities
- Expanding into emerging markets
- Developing new products and technologies
- Acquiring complementary businesses
- Increasing focus on specialty lenses
- Growing demand for minimally invasive surgical procedures
Threats
- Intense competition
- Pricing pressures
- Regulatory changes
- Economic downturns
- Product liability claims
Competitors and Market Share
Key Competitors
- ALC
- JNJ
- COPR
Competitive Landscape
Bausch + Lomb operates in a competitive landscape with a number of established players. The company's advantages include its strong brand recognition, diverse product portfolio, and global distribution network. Disadvantages include the high debt levels and competition.
Major Acquisitions
ISTA Pharmaceuticals
- Year: 2012
- Acquisition Price (USD millions): 500
- Strategic Rationale: Expanded its ophthalmic pharmaceutical portfolio.
Growth Trajectory and Initiatives
Historical Growth: Bausch + Lomb's historical growth has been driven by a combination of organic growth and acquisitions. The growth trends are constantly evolving and dependent on external factors such as the economy.
Future Projections: Analyst estimates vary, but generally, projections include consistent revenue growth. Growth will depend on market conditions and innovation.
Recent Initiatives: Recent strategic initiatives include expanding its product portfolio through research and development, geographic expansion, and strategic acquisitions.
Summary
Bausch + Lomb is a major player in the global eye care market, boasting a strong brand and diverse product portfolio. While it faces challenges such as high debt and intense competition, the company is positioned for growth through strategic initiatives and expansion into emerging markets. The company is investing in research and development, and should stay on top of pricing competition, as well as global economic down turns to protect its brand and position. In the future, they also need to look out for competitors with novel products as they emerge.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports
- Industry analysis reports
- News articles
- Analyst estimates
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bausch + Lomb Corp
Exchange NYSE | Headquaters Vaughan, ON, Canada | ||
IPO Launch date 2022-05-06 | CEO & Chairman Mr. Brenton L. Saunders J.D. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 13500 | Website https://www.bausch.com |
Full time employees 13500 | Website https://www.bausch.com | ||
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.